Logo image of AKRO

AKERO THERAPEUTICS INC (AKRO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AKRO - US00973Y1082 - Common Stock

54.65 USD
+0.1 (+0.18%)
Last: 12/8/2025, 8:00:00 PM
54.7 USD
+0.05 (+0.09%)
After Hours: 12/8/2025, 8:00:00 PM
Fundamental Rating

3

Overall AKRO gets a fundamental rating of 3 out of 10. We evaluated AKRO against 525 industry peers in the Biotechnology industry. While AKRO has a great health rating, there are worries on its profitability. AKRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AKRO had negative earnings in the past year.
  • AKRO had a negative operating cash flow in the past year.
  • AKRO had negative earnings in each of the past 5 years.
  • In the past 5 years AKRO always reported negative operating cash flow.
AKRO Yearly Net Income VS EBIT VS OCF VS FCFAKRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • The Return On Assets of AKRO (-29.12%) is better than 67.86% of its industry peers.
  • AKRO has a Return On Equity of -30.58%. This is in the better half of the industry: AKRO outperforms 75.94% of its industry peers.
Industry RankSector Rank
ROA -29.12%
ROE -30.58%
ROIC N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
AKRO Yearly ROA, ROE, ROICAKRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • AKRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKRO Yearly Profit, Operating, Gross MarginsAKRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for AKRO has been increased compared to 1 year ago.
  • AKRO has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AKRO has been reduced compared to a year ago.
AKRO Yearly Shares OutstandingAKRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AKRO Yearly Total Debt VS Total AssetsAKRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • AKRO has an Altman-Z score of 54.61. This indicates that AKRO is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 54.61, AKRO belongs to the best of the industry, outperforming 96.99% of the companies in the same industry.
  • There is no outstanding debt for AKRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 54.61
ROIC/WACCN/A
WACCN/A
AKRO Yearly LT Debt VS Equity VS FCFAKRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 15.83 indicates that AKRO has no problem at all paying its short term obligations.
  • AKRO's Current ratio of 15.83 is amongst the best of the industry. AKRO outperforms 92.29% of its industry peers.
  • A Quick Ratio of 15.83 indicates that AKRO has no problem at all paying its short term obligations.
  • The Quick ratio of AKRO (15.83) is better than 92.29% of its industry peers.
Industry RankSector Rank
Current Ratio 15.83
Quick Ratio 15.83
AKRO Yearly Current Assets VS Current LiabilitesAKRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.53% over the past year.
EPS 1Y (TTM)0.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • AKRO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.73% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.02%
EPS Next 2Y-8.27%
EPS Next 3Y-7.1%
EPS Next 5Y20.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKRO Yearly Revenue VS EstimatesAKRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
AKRO Yearly EPS VS EstimatesAKRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • AKRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKRO Price Earnings VS Forward Price EarningsAKRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKRO Per share dataAKRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • AKRO's earnings are expected to decrease with -7.10% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.27%
EPS Next 3Y-7.1%

More info and screens

0

5. Dividend

5.1 Amount

  • AKRO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AKERO THERAPEUTICS INC

NASDAQ:AKRO (12/8/2025, 8:00:00 PM)

After market: 54.7 +0.05 (+0.09%)

54.65

+0.1 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)02-26
Inst Owners102.85%
Inst Owner Change-0.64%
Ins Owners1.49%
Ins Owner Change-34.7%
Market Cap4.50B
Revenue(TTM)N/A
Net Income(TTM)-292.82M
Analysts72.5
Price Target64.26 (17.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.5%
Min EPS beat(2)-4.15%
Max EPS beat(2)7.14%
EPS beat(4)3
Avg EPS beat(4)6.96%
Min EPS beat(4)-4.15%
Max EPS beat(4)15.77%
EPS beat(8)5
Avg EPS beat(8)2.53%
EPS beat(12)8
Avg EPS beat(12)7%
EPS beat(16)10
Avg EPS beat(16)4.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.18%
EPS NQ rev (1m)4.2%
EPS NQ rev (3m)1.05%
EPS NY rev (1m)-1.91%
EPS NY rev (3m)0.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.7
P/tB 4.7
EV/EBITDA N/A
EPS(TTM)-3.73
EYN/A
EPS(NY)-4.4
Fwd EYN/A
FCF(TTM)-3.04
FCFYN/A
OCF(TTM)-3.04
OCFYN/A
SpS0
BVpS11.63
TBVpS11.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.12%
ROE -30.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.83
Quick Ratio 15.83
Altman-Z 54.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y-1.02%
EPS Next 2Y-8.27%
EPS Next 3Y-7.1%
EPS Next 5Y20.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.12%
EBIT Next 3Y-10.65%
EBIT Next 5YN/A
FCF growth 1Y-104.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.64%
OCF growth 3YN/A
OCF growth 5YN/A

AKERO THERAPEUTICS INC / AKRO FAQ

Can you provide the ChartMill fundamental rating for AKERO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to AKRO.


Can you provide the valuation status for AKERO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to AKERO THERAPEUTICS INC (AKRO). This can be considered as Overvalued.


What is the profitability of AKRO stock?

AKERO THERAPEUTICS INC (AKRO) has a profitability rating of 1 / 10.


How financially healthy is AKERO THERAPEUTICS INC?

The financial health rating of AKERO THERAPEUTICS INC (AKRO) is 8 / 10.


What is the expected EPS growth for AKERO THERAPEUTICS INC (AKRO) stock?

The Earnings per Share (EPS) of AKERO THERAPEUTICS INC (AKRO) is expected to decline by -1.02% in the next year.